Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4

曲妥珠单抗 癌症研究 单克隆抗体 受体酪氨酸激酶 人源化抗体 乳腺癌 抗体 酪氨酸激酶 癌症 医学 受体 生物 免疫学 内科学
作者
Joan Albanell,Jordi Codony,Ana Rovira,Begoña Mellado,Pere Gascón
出处
期刊:Advances in Experimental Medicine and Biology [Springer Nature]
卷期号:: 253-268 被引量:214
标识
DOI:10.1007/978-1-4615-0081-0_21
摘要

The HER family of transmembrane tyrosine kinase receptors is composed of four members, HER1 to HER4. HER2 is a ligand-orphan receptor expressed in many human tumors and overexpressed in 25-30% of breast cancers. HER2 amplifies the signal provided by other receptors of the HER family by forming heterodimers. The essential role of HER2 in the HER signaling network led to the development of anti-HER2 monoclonal antibodies (MAbs) for cancer therapy. In particular, the humanized MAb trastuzumab (Herceptin) has antitumor activity against HER2-overexpressing human breast tumor cells and is widely used for the treatment of women with HER2 overexpressing breast cancers. Trastuzumab induces HER2 receptor downmodulation and, as a result, inhibits critical signalling pathways (i.e. ras-Raf-MAPK and PI3K/Akt) and blocks cell cycle progression by inducing the formation of p27/Cdk2 complexes. Trastuzumab also inhibits HER2 cleavage, preceding antibody-induced receptor downmodulation, and this effect might contribute to its antitumor activity in some cancers.In vivotrastuzumab inhibits angiogenesis and induces antibody-dependent cellular cytotoxicity. A limitation of trastuzumab is that its activity is largely restricted to breast cancers with the highest level of HER2 overexpression or HER2 gene amplification. However, there is a large population of breast cancers and of many other tumors that have low or moderate HER2 expression. In such tumors, HER2 functions as a preferred coreceptor to form heterodimers with HER! (EGFR), HER3 or HER4. For this reason, a humanized monoclonal antibody, called 2C4, that targets the role of HER2 as a coreceptor is under active development. 2C4 binds to a different epitope of HER2 ectodomain than trastuzumab and sterically hinders HER2 recruitment in heterodimers with other HER receptors. This results in the inhibition of signalling by HER2-based heterodimers both in cells with low and high HER2 expression.In vitro andin vivo antitumor activity has been reported in a range of breast and prostate tumor models. Therefore, 2C4 may have potential against a wide variety of solid tumors. Phase I trials are underway.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
molihuakai的应助被沐夏采纳,获得10
刚刚
风吹麦浪的应助被玉溪采纳,获得20
刚刚
我考上啦完成签到 ,获得积分10
刚刚
斯文败类的应助被徐枘采纳,获得10
刚刚
stackheap发布了新的文献求助10
刚刚
之之怪完成签到,获得积分10
1秒前
Fiszh发布了新的文献求助20
1秒前
小唐发布了新的文献求助10
1秒前
4秒前
热情曲奇发布了新的文献求助10
4秒前
Jasper完成签到,获得积分10
5秒前
369ninja发布了新的文献求助10
5秒前
65935604完成签到,获得积分10
5秒前
上官若男的应助被北风北风采纳,获得10
5秒前
6秒前
6秒前
情怀的应助被眯眯眼的谷冬采纳,获得10
7秒前
沉默凡霜完成签到,获得积分10
7秒前
9秒前
10秒前
我是老大的应助被坚强孤容采纳,获得10
11秒前
12秒前
叉叉发布了新的文献求助10
12秒前
12秒前
Akim的应助被郭娅楠采纳,获得10
13秒前
14秒前
15秒前
阿皮的应助被dxxxxx采纳,获得30
15秒前
planb发布了新的文献求助10
15秒前
16秒前
16秒前
安详的琳完成签到 ,获得积分10
16秒前
大模型的应助被rareseason采纳,获得10
17秒前
sfliufighting发布了新的文献求助10
18秒前
chc发布了新的文献求助10
18秒前
18秒前
369ninja发布了新的文献求助10
19秒前
含糊的时光完成签到,获得积分10
19秒前
研友_ZGR30n发布了新的文献求助10
19秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817